Latest Conference Articles

Need for Biosimilar Cooperation Among Hospitals, Infusion Centers, and Payers Is Identified

Skylar Jeremias

October 22 2020

Overcoming biosimilar uptake barriers will take collaboration and policy change by hospitals, infusion clinics, and health plans, presenters said at the Academy of Managed Care Pharmacy Nexus 2020 Virtual conference.

Promising Results in CD, UC for Celltrion Infliximab Biosimilar

Skylar Jeremias

October 12 2020

Celltrion Healthcare reports on progress with higher predose levels of the infliximab biosimilar Remsima in patients with Crohn disease (CD) and ulcerative colitis (UC).

International Presenters Share Tips on Beefing Up Biosimilar Use

Skylar Jeremias

October 9 2020

As the United States continues to struggle to increase biosimilar uptake, presenters at the DIA 2020 Biosimilars Conference offered insight into what other countries have done to encourage biosimilar use.

FDA Reshuffles Priorities to Meet COVID-19 Trial Demand

Tony Hagen

October 7 2020

The FDA has had to rely on triaging to address its most critical priorities during the unfolding coronavirus disease 2019 (COVID-19) pandemic, according to Peter P. Stein, MD.

Meier Explains FTC's Power to Pursue Antitrust Activity

Tony Hagen

September 30 2020

The Federal Trade Commission's powers to bring antitrust actions are circumscribed by public versus private and what is vs isn't "reasonable," Markus H. Meier explained.

FTC's Markus H. Meier Talks About Restraint of Trade in the Biosimilar Marketplace

Tony Hagen

September 28 2020

Some acts by companies in the biologics marketplace may go too far in preventing free market activity, according to Markus H. Meier, acting director for the Federal Trade Commission (FTC) Bureau of Competition.

Patt: Payers Could Save More With Biosimilars

Tony Hagen

September 25 2020

Debra Patt, MD, PhD, MBA, discusses issues affecting biosimilar uptake at the Patient-Centered Oncology Care® 2020 virtual conference.

Biopharmaceutical Industry Representatives Discuss Product Hopping Legislation

Tony Hagen

September 24 2020

Two bills in Congress meant to address the anticompetitive practice of product hopping drew fire at the American Conference Institute's annual biosimilars conference.

FDA's Eva Temkin Discusses Biosimilar Approvals at ACI

Tony Hagen

September 23 2020

The FDA's Office of Therapeutic Biologics and Biosimilars balances a large number of biosimilar development projects with limited resources and is making progress, says Eva Temkin, acting director of policy.

California's Anticompetitive Legislation Is Scrutinized at ACI

Tony Hagen

September 23 2020

Panelists at American Conference Institute's (ACI) 2020 virtual summit discuss California's legislative attempts to improve competition in the drug industry.